Stroke guidelines
Reading File
Asking for Preferences
Finding Sources
Searching PubMed
"ischemic stroke"[MeSH Terms] AND "guidelines"
Searching the Web
AHA ASA ischemic stroke acute management guidelines 2024 2025
Reading File
Reading File
Reading Web Page
acute ischemic stroke management tPA thrombolysis thrombectomy time windows blood pressure
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple textbooks and the brand-new 2026 AHA/ASA guideline. Let me compile a thorough response.
Acute Ischemic Stroke (AIS) - Management Guidelines
Important update: The AHA/ASA released a 2026 Guideline for the Early Management of Patients with Acute Ischemic Stroke (replaces the 2018 guideline and its 2019 update). Key changes are noted below.
1. Initial Evaluation & Stabilization
Prehospital / ED arrival priorities:
- Activate stroke team immediately; aim for door-to-needle time <60 minutes for tPA
- Airway, breathing, circulation assessment; pulse oximetry; supplemental O2 if SpO2 <94%
- Avoid hyperthermia (worsens ischemic outcome); treat fever aggressively
- 12-lead ECG + troponin on arrival (cardiac monitoring for at least 48 h; 3-20% of strokes have concomitant myocardial ischemia)
- Blood work: CBC, PT/INR, aPTT, BMP, glucose
Imaging:
- Non-contrast CT (NCCT) head immediately - rules out hemorrhage
- CT angiography (CTA) ± CT perfusion for thrombectomy candidates or extended-window thrombolysis
Stroke units: All stroke/TIA patients presenting within 72 h should be admitted, preferably to a dedicated stroke unit (associated with lower mortality, shorter LOS, less nursing home discharge).
2. Blood Pressure Management
| Clinical scenario | BP target |
|---|---|
| Pre-tPA | Must be <185/110 mmHg before giving tPA; use IV labetalol or nicardipine |
| Post-tPA (first 24 h) | Maintain <180/105 mmHg |
| Not receiving tPA, no reperfusion | Permissive hypertension; avoid lowering unless >220/120 mmHg |
| Post-EVT | Target SBP 130-180 mmHg (post-2026 guidance) |
Optimal SBP in the acute phase without intervention appears to be 160-200 mmHg - overtreating causes hypotension and worsens ischemic penumbra. Autoregulation is impaired.
3. IV Thrombolysis (tPA / Alteplase)
Dosing
Alteplase 0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 min, remainder over 60 min.
Time windows and eligibility (2019/2026 AHA/ASA)
| Window | Recommendation |
|---|---|
| 0-3 hours | Recommended for all eligible patients ≥18 years (including >80 years, severe stroke, mild-disabling stroke) |
| 3-4.5 hours | Recommended for patients ≤80 years, no history of both DM + prior stroke, NIHSS ≤25, not on OAC, and infarct not involving >1/3 MCA territory |
| 4.5-9 hours (extended, new 2026) | Reasonable (COR 2a) if salvageable penumbra on automated perfusion imaging AND either (a) wake-up stroke within 9 h of sleep midpoint or (b) 4.5-9 h from last known well |
Key exclusions
- BP >185/110 mmHg (untreatable)
- Active internal bleeding, recent major surgery <14 days
- Recent intracranial or spinal surgery, head trauma, or stroke <3 months
- Platelet count <100,000; INR >1.7; aPTT elevated
- Direct thrombin or Xa inhibitors: do NOT give tPA unless aPTT, INR, platelet count are normal or last dose >48 h ago (normal renal function)
- LMWH full treatment dose within previous 24 h: contraindicated
- Prior ICH
Symptomatic ICH risk
Occurs in 2-7% post-tPA; highest in most severe strokes. Usually within 36 h (50% within 5-10 h). Asymptomatic ICH is more frequent.
4. Tenecteplase - 2026 Update
The 2026 guideline now endorses tenecteplase as an alternative to alteplase for patients without large vessel occlusion (LVO). A 2024 meta-analysis (PMID: 39413337) of RCTs showed tenecteplase is non-inferior to alteplase within 4.5 hours. Tenecteplase is given as a single IV bolus (0.25 mg/kg, max 25 mg), which simplifies administration.
5. Endovascular Thrombectomy (EVT)
Standard window: 0-6 hours (COR 1 - Strong recommendation)
Criteria (2026 AHA/ASA):
- Anterior circulation proximal LVO (ICA or M1 segment)
- NIHSS ≥6
- Prestroke mRS 0-1
- ASPECTS 3-10 (note: 2026 expanded from prior ASPECTS ≥6 threshold)
- Perform regardless of whether tPA was given
Extended window: 6-24 hours
| Window | Trial | Criteria |
|---|---|---|
| 6-16 h | DAWN, DEFUSE 3 | Clinical-imaging mismatch (age/NIHSS/core infarct volume criteria); anterior circulation LVO |
| 16-24 h | DAWN | Age ≥80 + NIHSS ≥10 + core <21 mL; or age <80 + NIHSS ≥10 + core <31 mL; or age <80 + NIHSS ≥20 + core <51 mL |
Time is critical: Each 1-hour delay to reperfusion = measurably worse functional outcome. After 7 hours from onset, benefit becomes non-significant in pooled data.
Distal/posterior circulation occlusions: Benefits are less certain for M2/M3 MCA, ACA, vertebral, basilar, or PCA occlusions (basilar is often treated despite limited evidence given the devastating natural history).
6. Glucose Management
- Treat hypoglycemia immediately (glucose <60 mg/dL mimics stroke)
- Avoid hyperglycemia but intensive insulin control is NOT recommended - the SHINE Trial showed no benefit and increased hypoglycemia risk
- Optimal target glucose in acute stroke remains uncertain
7. Cerebral Edema Management
- Edema peaks at 72-120 hours post-stroke
- Corticosteroids are NOT indicated for ischemic cerebral edema (no proven benefit, increase infections)
- Osmotherapy (mannitol, hypertonic saline) for raised ICP
- Hemicraniectomy: Decompressive surgery within 48 h is life-saving for malignant MCA infarction (large dominant/non-dominant hemisphere strokes), particularly in younger patients
8. Antiplatelet / Antithrombotic Therapy
- Aspirin 325 mg within 24-48 h of stroke onset (not within 24 h of tPA)
- Dual antiplatelet (aspirin + clopidogrel) for 21 days for minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), then transition to monotherapy - based on POINT and CHANCE trials
- Anticoagulation: Not recommended for acute cardioembolic stroke in first 24-48 h if large infarct (hemorrhagic transformation risk); timing depends on infarct size and source
9. Key Time Metrics (AHA/ASA targets)
| Metric | Target |
|---|---|
| Door-to-CT | ≤25 minutes |
| Door-to-needle (tPA) | ≤60 minutes |
| Door-to-groin puncture (EVT) | ≤90 minutes |
| Symptom onset to treatment | As fast as possible - "time is brain" |
Sources
- Bradley and Daroff's Neurology in Clinical Practice, p. 1405-1406
- Rosen's Emergency Medicine, p. 1435-1439 (Table 87.5: 2019 AHA/ASA Alteplase Guidelines)
- 2026 AHA/ASA Guideline for Early Management of AIS (ahajournals.org) - replaces 2018 guideline
- Palaiodimou et al. 2024, Neurology - Tenecteplase vs Alteplase meta-analysis [PMID: 39413337]
This is a shared conversation. Sign in to Orris to start your own chat.